Farom

Farom Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative multi-specific antibodies for oncology and autoimmune disorders. The company utilizes a proprietary technology platform to design bispecific and trispecific antibodies that enhance immune cell engagement and tumor targeting. Its lead asset, FRM-001, is a CD19/CD3 bispecific antibody currently undergoing clinical evaluation for B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Farom also advances a pipeline of candidates targeting HER2 and BCMA, maintaining research and development facilities in both Suzhou, China, and Boston, Massachusetts. The company aims to address significant unmet clinical needs through its specialized protein engineering capabilities and strategic focus on immunotherapy.